Comment on "Early Prognostic Utility of Gp210 Antibody-Positive Rate in Primary Biliary Cholangitis: A Meta-Analysis".
作者信息
Cristoferi Laura, Invernizzi Pietro
机构信息
Division of Gastroenterology and Center for Autoimmune Liver Diseases, San Gerardo Hospital, Department of Medicine and Surgery, University of Milano Bicocca, Monza, Italy.
出版信息
Dis Markers. 2020 Jan 22;2020:2453908. doi: 10.1155/2020/2453908. eCollection 2020.
Abstract
摘要
相似文献
1
Comment on "Early Prognostic Utility of Gp210 Antibody-Positive Rate in Primary Biliary Cholangitis: A Meta-Analysis".对“原发性胆汁性胆管炎中Gp210抗体阳性率的早期预后价值：一项荟萃分析”的评论
Dis Markers. 2020 Jan 22;2020:2453908. doi: 10.1155/2020/2453908. eCollection 2020.
2
The antinuclear autoantibodies Sp100 and gp210 persist after orthotopic liver transplantation in patients with primary biliary cirrhosis.原发性胆汁性肝硬化患者原位肝移植后，抗核自身抗体Sp100和gp210持续存在。
J Hepatol. 1998 May;28(5):824-8. doi: 10.1016/s0168-8278(98)80233-x.
3
Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis.原发性胆汁性肝硬化中抗核抗体的特征及临床影响
Am J Gastroenterol. 2003 Feb;98(2):431-7. doi: 10.1111/j.1572-0241.2003.07257.x.
4
Early Prognostic Utility of Gp210 Antibody-Positive Rate in Primary Biliary Cholangitis: A Meta-Analysis.原发性胆汁性胆管炎中 Gp210 抗体阳性率的早期预后价值：一项荟萃分析。
Dis Markers. 2019 Oct 13;2019:9121207. doi: 10.1155/2019/9121207. eCollection 2019.
5
[Anti-Sp100 and anti-Gp210 in the diagnosis of primary biliary cirrhosis in patients with autoimmune cholangitis].[抗Sp100和抗Gp210在自身免疫性胆管炎患者原发性胆汁性肝硬化诊断中的应用]
Gastroenterol Hepatol. 1999 Jan;22(1):11-3.
6
Meta-analysis assessment of GP210 and SP100 for the diagnosis of primary biliary cirrhosis.GP210和SP100用于原发性胆汁性肝硬化诊断的Meta分析评估
PLoS One. 2014 Jul 10;9(7):e101916. doi: 10.1371/journal.pone.0101916. eCollection 2014.
7
Anti-gp210 and other anti-nuclear pore complex autoantibodies in primary biliary cholangitis: What we know and what we should know.原发性胆汁性胆管炎中的抗糖蛋白210及其他抗核孔复合体自身抗体：我们所知道的和我们应该知道的。
Liver Int. 2021 Mar;41(3):432-435. doi: 10.1111/liv.14791.
8
Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis.抗 gp210 抗体与原发性胆汁性胆管炎患者的风险评估。
Liver Int. 2021 Mar;41(3):535-544. doi: 10.1111/liv.14688.
9
Anti-gp210 and anti-Sp100 antibodies in primary biliary cholangitis.原发性胆汁性胆管炎中的抗 gp210 和抗 Sp100 抗体。
Arab J Gastroenterol. 2021 Dec;22(4):316-320. doi: 10.1016/j.ajg.2021.05.006. Epub 2021 Jun 3.
10
Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis.抗糖蛋白210抗体和抗着丝粒抗体是原发性胆汁性肝硬化进展的不同危险因素。
Hepatology. 2007 Jan;45(1):118-27. doi: 10.1002/hep.21472.
本文引用的文献
1
Early Prognostic Utility of Gp210 Antibody-Positive Rate in Primary Biliary Cholangitis: A Meta-Analysis.原发性胆汁性胆管炎中 Gp210 抗体阳性率的早期预后价值：一项荟萃分析。
Dis Markers. 2019 Oct 13;2019:9121207. doi: 10.1155/2019/9121207. eCollection 2019.
2
EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis.EASL 临床实践指南：原发性胆汁性胆管炎患者的诊断和管理。
J Hepatol. 2017 Jul;67(1):145-172. doi: 10.1016/j.jhep.2017.03.022. Epub 2017 Apr 18.
3
Interpreting serological tests in diagnosing autoimmune liver diseases.自身免疫性肝病诊断中血清学检测结果的解读
Semin Liver Dis. 2007 May;27(2):161-72. doi: 10.1055/s-2007-979469.
4
Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis.原发性胆汁性肝硬化中初始自身抗体谱与临床结局的相关性
Hepatology. 2006 May;43(5):1135-44. doi: 10.1002/hep.21172.
5
Antinuclear antibodies in primary biliary cirrhosis.原发性胆汁性肝硬化中的抗核抗体
Semin Liver Dis. 2005 Aug;25(3):298-310. doi: 10.1055/s-2005-916321.
6
Prognosis in primary biliary cirrhosis: model for decision making.原发性胆汁性肝硬化的预后：决策模型
Hepatology. 1989 Jul;10(1):1-7. doi: 10.1002/hep.1840100102.
Zotero 插件